10-K: Bellevue Life Sciences Acquisition Corp. Files 10-K, Outlines Business Combination Strategy and Financials

Bellevue Life Sciences Acquisition Corp.'s 10-K filing details its financial status, ongoing efforts to secure a business combination, and strategic focus on the healthcare sector.

Summary

• Bellevue Life Sciences Acquisition Corp., a blank check company, filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.
• The company is focused on identifying a business combination within the healthcare industry, particularly in the biotechnology sector.
• As of December 31, 2023, the company held $34,535,106 in its trust account, after accounting for deferred underwriting fees.
• The company has extended its deadline to complete a business combination to May 14, 2024, and has secured additional funding through promissory notes.
• A proposed business combination agreement with OSR Holdings Co. Ltd. has been entered into, with closing conditions including a minimum available cash condition of $5,000,001.
• The company reported a net income of $403,780 for the year ended December 31, 2023, primarily due to interest income from the trust account.
• The company has identified material weaknesses in its internal control over financial reporting related to the review and approval of certain financial transactions, including use of restricted funds for general corporate purposes and related party transactions.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in securing a business combination agreement and extending its deadline, the identified material weaknesses in internal control, the Nasdaq non-compliance notices, and the working capital deficiency raise significant concerns. The company's future is uncertain, and the risks outweigh the positives at this stage.

Positives

• The company has secured a business combination agreement with OSR Holdings Co. Ltd.
• The company has extended its deadline to complete a business combination, providing more time to finalize a deal.
• The company generated a net income of $403,780 for the year ended December 31, 2023, primarily from interest income.
• The company has a clear strategy to focus on the healthcare sector, particularly biotechnology.

Negatives

• The company has identified material weaknesses in its internal control over financial reporting.
• The company is not currently in compliance with Nasdaq listing rules regarding the audit committee composition.
• The company has received a notification from Nasdaq for not meeting the minimum 300 public holders requirement.
• The company has a working capital deficiency of $2,015,645 as of December 31, 2023.
• The company has a limited time to complete a business combination, which may give potential targets leverage in negotiations.

Risks

• The company may not be able to complete a business combination within the extended timeframe.
• The company's financial condition may be less attractive to potential targets due to redemption rights of public stockholders.
• The company may be subject to a 1% U.S. federal excise tax on redemptions of shares.
• The company may be deemed an investment company under the Investment Company Act, which would severely restrict its activities.
• The company may face intense competition from other entities seeking business combinations.
• The company's ability to complete a business combination may be affected by ongoing military conflicts and related humanitarian crises.
• The company has material weaknesses in its internal control over financial reporting, which could lead to misstatements in financial reports.
• The company may be subject to U.S. foreign investment regulations and review by CFIUS, which could delay or block a business combination.

Future Outlook

The company is focused on completing its business combination with OSR Holdings Co. Ltd. by May 14, 2024, and is actively seeking additional financing. The company's future success depends on the performance of the target business and its ability to navigate the risks associated with the healthcare industry.

Management Comments

• Management intends to complete a business combination.
• Management is currently evaluating the full impact and the possible negative effect these conflicts could have on the Companys financial position, results of its operations and/or search for a target company.

Industry Context

The company's focus on the healthcare industry, particularly biotechnology, aligns with current trends in the market, where there is significant interest and investment in innovative healthcare solutions. The company's portfolio investment approach via a holding company model is designed to mitigate risks associated with investing in a single company.

Comparison to Industry Standards

• The company's financial performance is typical for a SPAC in its pre-business combination phase, with limited operating revenue and reliance on interest income from the trust account.
• The company's focus on the healthcare sector is a common strategy among SPACs, given the potential for high growth and innovation in this industry.
• The company's identified material weaknesses in internal control over financial reporting are not uncommon for early-stage companies, but require remediation to ensure accurate financial reporting.
• The company's proposed business combination with OSR Holdings is similar to other SPAC transactions, involving a merger or acquisition of a private company to take it public.

Corporate Governance

Related Party Transactions

• The company has entered into various transactions with its Sponsor and related parties, including the purchase of founder shares, private placement units, and promissory notes.
• The company has agreed to pay an affiliate of its Sponsor a monthly fee for office space, utilities, and administrative support.
• The company may pay BCM and/or any of its affiliates, partners or employees a fee for financial advisory services rendered in connection with our initial business combination.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company fails to complete a business combination.
• Shareholders may be subject to dilution if the company issues additional shares to finance a business combination.
• Employees of the target business may be affected by the terms of the business combination.
• Creditors of the company may have claims against the trust account if the company fails to complete a business combination.

Next Steps

• The company will seek to complete its business combination with OSR Holdings Co. Ltd.
• The company will work to regain compliance with Nasdaq listing rules.
• The company will continue to seek additional financing to support its operations and business combination.
• The company will remediate the identified material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

business combination, healthcare, biotechnology, SPAC, OSR Holdings, trust account, redemption, internal control, Nasdaq, promissory notes